KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Net Cash Flow (2016 - 2026)

Thermo Fisher Scientific filings provide 18 years of Net Cash Flow readings, the most recent being -$6.7 billion for Q1 2026.

  • On a quarterly basis, Net Cash Flow fell 7202.13% to -$6.7 billion in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.2 billion, a 5.82% increase, with the full-year FY2025 number at $5.6 billion, up 240.49% from a year prior.
  • Net Cash Flow hit -$6.7 billion in Q1 2026 for Thermo Fisher Scientific, down from $7.9 billion in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $7.9 billion in Q4 2025 to a low of -$6.7 billion in Q1 2026.
  • Median Net Cash Flow over the past 5 years was -$356.0 million (2024), compared with a mean of -$73.1 million.
  • Biggest five-year swings in Net Cash Flow: skyrocketed 2311.8% in 2025 and later tumbled 7202.13% in 2026.
  • Thermo Fisher Scientific's Net Cash Flow stood at $5.4 billion in 2022, then tumbled by 64.15% to $1.9 billion in 2023, then tumbled by 118.55% to -$356.0 million in 2024, then skyrocketed by 2311.8% to $7.9 billion in 2025, then crashed by 184.79% to -$6.7 billion in 2026.
  • The last three reported values for Net Cash Flow were -$6.7 billion (Q1 2026), $7.9 billion (Q4 2025), and -$2.5 billion (Q3 2025) per Business Quant data.